Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. [electronic resource]
Producer: 20100622Description: 884-894 p. digitalISSN:- 1569-8041
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Biomarkers, Pharmacological -- analysis
- Cohort Studies
- Cyclin-Dependent Kinases -- antagonists & inhibitors
- Disease Progression
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Imidazoles -- administration & dosage
- Male
- Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.